Renal cell carcinoma (RCC) is a highly vascularized tumor and prone to distant metastasis, the prospect potential approaches to overcome RCC resistance is important to guide individualized and precision drug therapy. In response to this, the editorial office of Cancer Drug Resistance organized the special issue “Resistance to Systemic Therapies in Renal Cell Carcinoma” which is guest-edited by Guru P. Sonpavde, a leading expert in this field.
On 8 July 2022, the editorial office was honored to invite Prof. Guru P. Sonpavde to share his latest research and future prospects in the field of Renal Cell Carcinoma. At the end, Prof. Guru P. Sonpavde concluded by stating his hopes for the special issue: to gather experts in the field to discuss the current status and share their cutting-edge perspectives.
Details of the interview
Guru P. Sonpavde, MD is the director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School. He is a member of the Genitourinary Committee of Southwest Oncology Group and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Steering Committee. His main areas of expertise are Renal Cell Carcinoma, Bladder cancer, Novel therapies, Prostate cancer,Testicular cancer, Penile cancer, and so on.
Q1.We’ve noticed that you’ve been working on Genitourinary Oncology for a long time. Can you share with us what motivates you to keep working on this? Do you and your team have any latest research progress on it?
Q2. As an outstanding scientist in the field of renal cell carcinoma resistance, what do you think are the challenges that you face in this field? Could you talk about the Current research hotspots in this field?
Q3. What do you think of the future prospects in the field of Renal Cell Carcinoma resistance?
Q4. As the guest editor of the CDR, Do you have any suggestions for the current development of CDR?
The editorial office and Prof. Sonpavde share the same vision and hope to promote the development of Cancer Drug Resistance by gathering experts in the field to discuss the latest issues and solutions.
Welcome to follow the updated information of the special issue through: https://cdrjournal.com/journal/special_detail/1152
If you would like to contribute to this special issue, please submit the article thorough: https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR220525
Welcome to your submission
Cancer Drug Resistance